DGAP-News

MOLOGEN AG: First combination trial with MGN1703 and a checkpoint inhibitor in collaboration with MD Anderson - Seite 2

study.

Dr. Alfredo Zurlo, Chief Medical Officer (CMO) of MOLOGEN AG commented:
"Our study program with lefitolimod as monotherapy in colorectal and lung
cancer is well on track. We are now moving to explore for the first time
the combination of MGN1703 with a checkpoint inhibitor. Yervoy(R)
monotherapy can dramatically improve the outcome of a minority of melanoma
patients; we hope to show that the combination with MGN1703 can expand both
the frequency and potency of these responses."

"We look forward to learning more about this combination as ipilimumab and
MGN1703 each target distinct, yet essential components of the immune system
necessary to reject tumors. Boosting both of these arms in concert has
shown improved therapeutic responses in pre-clinical models relative to
either monotherapy alone", said Dr. Michael Curran, Assistant Professor,
Department of Immunology, MD Anderson Cancer Center, and collaborator on
the study.

MD Anderson will conduct the trial with around 50-60 patients at its center
in Houston Texas, US. MOLOGEN will provide the immunomodulator lefitolimod
(MGN1703). The study will open for patient enrollment within the next few
weeks.

MOLOGEN AG
With new and unique technologies and active substances, the biotech company
MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a
focus on immuno-oncology, MOLOGEN also develops immunotherapies for the
treatment of infectious diseases.

The cancer immunotherapy lefitolimod (MGN1703) is the company's lead
product and best-in-class TLR9 agonist. Treatment with MGN1703 triggers a
broad and strong activation of the immune system. Due to this mechanism of
action, MGN1703 has the potential to be applied to various indications.
MGN1703 is currently being developed for first-line maintenance treatment
of colorectal cancer (pivotal study) and small cell lung cancer (randomized
controlled trial). Furthermore it is also being investigated in a phase I
study in HIV.

MOLOGEN's pipeline focus is on new innovative immunotherapies to treat
diseases for which there is a high medical need.

www.mologen.com

Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.
| DECHEMA - Society for chemical technology and biotechnology e.V. |
German industrial association of biotechnology (DIB) | Association for
the Promotion of Science and Humanities in Germany | Association of
German biotechnology companies (VBU) | Association of researching
manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical